

In the Claims

1-6 (canceled).

7 (new). A pharmaceutical composition comprising a form of a propylene glycol solvate of an active pharmaceutical ingredient (API) selected from olanzapine, cortisone acetate, naproxen, celecoxib trihydrate, celecoxib or salts thereof.

8 (new). The composition according to claim 7, wherein the API is olanzapine and the composition is characterized by a powder x-ray diffraction (PXRD) pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- a) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 15.61, and 21.41 degrees; or
- b) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.95, 14.47, 22.03, and 23.29 degrees; or
- c) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 17.95, 19.57, and 20.65 degrees; or
- d) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 8.95, 14.47, 15.61, 17.95, and 23.29 degrees; or
- e) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 15.61, and 20.65 degrees; or
- f) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33 and 21.41 degrees; or
- g) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 14.47 degrees; or
- i) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47 and 22.03 degrees; or

j) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 17.95 and 20.65 degrees; or

k) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 8.33 degrees.

9 (new). The composition according to claim 8, wherein:

a) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 15.61, and 21.41 degrees; or

b) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 8.95, 14.47, 15.61, 17.95, and 23.29 degrees; or

c) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33 and 21.41 degrees.

10 (new). The composition according to claim 8, wherein said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 8.33 degrees.

11 (new). The composition according to claim 8, wherein:

a) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.95, 14.47, 22.03, and 23.29 degrees; or

b) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 17.95, 19.57, and 20.65 degrees; or

c) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 15.61, and 20.65 degrees; or

d) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47 and 22.03 degrees.

12 (new). The composition according to claim 8, wherein said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 14.47 degrees.

13 (new). The composition according to claim 8, wherein said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 17.95 and 20.65 degrees.

14 (new). The composition according to claim 7, wherein the API is cortisone acetate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- a) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 10.71, 14.54, and 18.49 degrees; or
- b) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 15.66, 21.33, and 23.49 degrees; or
- c) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 10.71, 14.54, 15.66, 18.49, 21.33, and 23.49 degrees; or
- d) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 14.54 and 18.49 degrees; or
- e) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 15.66 and 21.33 degrees; or
- f) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 5.31 degrees; or
- g) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 18.49.

15 (new). The composition according to claim 14, wherein said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 18.49.

16 (new). The composition according to claim 14, wherein said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 5.31 degrees.

17 (new). The composition according to claim 14, wherein:

- a) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 10.71, 14.54, and 18.49 degrees; or
- b) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 14.54 and 18.49 degrees.

18 (new). The composition according to claim 14, wherein said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 15.66 and 21.33 degrees.

19 (new). The composition according to claim 14, wherein:

- a) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 15.66, 21.33, and 23.49 degrees; or
- b) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 10.71, 14.54, 15.66, 18.49, 21.33, and 23.49 degrees.

20 (new). The composition according to claim 7, wherein the API is a sodium salt of naproxen and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- a) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 6.67, 18.55, and 22.79 degrees;
- b) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 9.65, 15.77, and 20.83 degrees;
- c) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 6.67 and 18.55 degrees;
- d) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises a peak at 9.65 degrees;
- f) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises a peak at 6.67 degrees;

g) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 15.77, 18.55, and 27.17 degrees; or

h) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 9.65 and 22.79 degrees.

21 (new). The composition according to claim 20, wherein said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises a peak at 9.65 degrees.

22 (new). The composition according to claim 20, wherein said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises a peak at 6.67 degrees.

23 (new). The composition according to claim 20, wherein:

- a) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 6.67, 18.55, and 22.79 degrees; or
- b) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 6.67 and 18.55 degrees.

24 (new). The composition according to claim 20, wherein said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 15.77, 18.55, and 27.17 degrees; or

25 (new). The composition according to claim 20, wherein:

- a) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 9.65 and 22.79 degrees; or
- b) said form is a propylene glycol solvate of a sodium salt of naproxen and said PXRD pattern comprises peaks at 9.65, 15.77, and 20.83 degrees.

26 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:

- a) any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more peaks selected from peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87 or 25.75 degrees; or
- b) any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61 or 25.71 degrees.

27 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising:

any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following peaks: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees

28 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by a PXRD pattern that comprises a peak at 8.21 degrees 2-theta.

29 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by a PXRD pattern that comprises a peak at 8.79 degrees 2-theta.

30 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of a calcium salt of celecoxib and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following: 3.75, 7.47, 11.33, 14.89, 15.65, 18.31, 20.49, 21.73, 22.51 or 24.97.

31 (new). The composition according to claim 7, wherein said form is a propylene glycol solvate of a lithium salt of celecoxib and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, said PXRD pattern comprising any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of 3.79, 7.51, 8.19, 9.83, 11.41, 15.93, 18.29, 19.19, 19.87, 20.63, 22.01 or 25.09.